BRISTOL-MYERS SQUIBB COMPANY

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$3,050,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Intellectual Property Reform concerning bio-pharmaceutical industry

Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade

Bills named in this filing 4

H.R. 7635
The 340B PATIENTS Act of 2024
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 5509
Safe Step Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.